Mania News and Research

RSS

Abilify (aripiprazole) approved for acute treatment of bipolar I disorder in adolescents

Otsuka Pharmaceutical Co., Ltd. and Bristol-Myers Squibb Company has announced that the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Application for ABILIFY (aripiprazole) for the acute treatment of manic and mixed episodes associated with Bipolar I Disorder, with or without psychotic features in pediatric patients (10 to 17 years old).

1 Mar 2008

Lilly knocked back by FDA on Zyprexa for schizophrenia treatment

Eli Lilly and Company has received a not approvable letter from the U.S. Food and Drug Administration for Zyprexa long-acting injection (olanzapine LAI) for the treatment and maintenance treatment of schizophrenia in adults, the company announced.

28 Feb 2008

Researchers isolate biomarkers in the blood that identify mood disorders

Indiana University School of Medicine researchers have isolated biomarkers in the blood that identify mood disorders, a breakthrough that may change the way bipolar illness is diagnosed and treated.

26 Feb 2008

People with manic depression have a distinct chemical signature in their brains

People with manic depression have a distinct chemical signature in their brains, according to a new study. The research, published in the journal Molecular Psychiatry, may also indicate how the mood stabilisers used to treat the disorder counteract the changes in the brain that it appears to cause.

5 Feb 2008

Study suggests Risperidone long-acting injection combined with standard treatment helped delay time to relapse in patients with bipolar disorder

Patients with frequently relapsing bipolar disorder had a significant delay in the time to an initial relapse when risperidone long-acting injection (RLAI) was combined with standard treatment, according to a new study. The study compared patients who received RLAI and standard treatment to those who received standard treatment combined with placebo.

4 Feb 2008

Bright light therapy helps some with bipolar depression

Bright light therapy can ease bipolar depression in some patients, according to a study published in the journal Bipolar Disorders.

4 Jan 2008

AstraZeneca submits sNDAs for SEROQUEL XR for bipolar symptoms

AstraZeneca has announced that the company has submitted two separate supplemental New Drug Applications (sNDAs) to the U.S. Food and Drug Administration (FDA) for once-daily SEROQUEL XR (quetiapine fumarate) Extended-Release Tablets to seek approval for the treatment of manic episodes associated with bipolar disorder and the treatment of depressive episodes associated with bipolar disorder.

3 Jan 2008

Stable sleep patterns and regular routines may improve outcomes in bipolar disorder

Bipolar disorder, commonly known as manic-depressive disorder, is highly influenced by the circadian system - the body's internal clock - and a specific kind of psychotherapy may help decrease irregularities in the circadian system that can trigger key symptoms of bipolar disorder, according to a study presented at the American College of Neuropsychopharmacology (ACNP) annual meeting.

10 Dec 2007

Children with bipolar disorder respond differently to facial expressions

Children with bipolar disorder respond differently to facial expressions than children without psychiatric disorders, according to a new study led by a Bradley Hospital researcher.

27 Nov 2007

FDA accepts Schering-Plough's new drug application for Asenapine

Schering-Plough Corporation has announced that the U.S. Food and Drug Administration (FDA) recently accepted the filing for review of the New Drug Application (NDA) for asenapine, a fast-dissolving, sublingual tablet.

26 Nov 2007

Myths and misunderstandings about bipolar disorder

Portrayals of bipolar disorder seem to be cropping up everywhere -- in the news, in movies, and on television.

31 Oct 2007

FDA warns about 'stay awake drug' Provigil

The U.S. Food and Drug Administration (FDA) has issued a warning in connection with the drug Provigil because of dangerous side effects.

28 Oct 2007

Breast cancer drug tamoxifen helps treat symptoms of bipolar disease

Government researchers in the United States have found that the breast cancer drug tamoxifen helped treat the manic symptoms of bipolar disease.

13 Sep 2007

Tamoxifen for bipolar disorder

The medication tamoxifen, best known as a treatment for breast cancer, dramatically reduces symptoms of the manic phase of bipolar disorder more quickly than many standard medications for the mental illness, a new study shows.

13 Sep 2007

Help for parents with bipolar disorder

Parents with bipolar disorder are taking part in a study that will give them the chance to follow a highly successful parenting skills programme.

From The University of Manchester 10 Sep 2007

Dramatic rise of bipolar disorder in young Americans

According to a new study there has been a dramatic rise in the number of young Americans diagnosed with bipolar disorder in recent years.

4 Sep 2007

Bipolar disorder a growing health issue

The estimated number of youth with office visits with a diagnosis of bipolar disorder substantially increased between 1994 and 2003, while adult visits with a bipolar disorder diagnoses appeared to almost double, according to a report in the September issue of Archives of General Psychiatry, one of the JAMA/Archives journals.

4 Sep 2007

Urgent need for better understanding of bipolar disease in children and adolescents

The number of visits to a doctor's office that resulted in a diagnosis of bipolar disorder in children and adolescents has increased by 40 times over the last decade, reported researchers funded in part by the National Institutes of Health (NIH).

4 Sep 2007

Seroquel XR tablets approved in Netherlands for the treatment of schizophrenia

AstraZeneca today announced the Netherlands regulatory authority MEB (Medicines Evaluation Board) has approved Seroquel XR (quetiapine fumarate) Extended-Release Tablets, a once-daily medicine for the treatment of schizophrenia in adult patients.

29 Aug 2007

New hope for people with bipolar disorder

Melbourne mental health researchers have succeeded in halving the number of relapses experienced by people with bipolar disorder which strikes two in 100 Australians, accounts for 12 per cent of suicides each year and costs the country at least $1.5 billion annually.

24 Aug 2007